CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $145 | -79.7% | 4,556 | -84.5% | 0.00% | -87.5% |
| Q1 2023 | $716 | +56.7% | 29,354 | +102.4% | 0.01% | +33.3% |
| Q4 2022 | $457 | -99.8% | 14,505 | +41.7% | 0.01% | +50.0% |
| Q3 2022 | $289,000 | -44.4% | 10,234 | -48.0% | 0.00% | -33.3% |
| Q2 2022 | $520,000 | +102.3% | 19,671 | +148.6% | 0.01% | +500.0% |
| Q4 2021 | $257,000 | -65.3% | 7,913 | -68.4% | 0.00% | -66.7% |
| Q3 2021 | $740,000 | -64.7% | 25,068 | -69.3% | 0.00% | -70.0% |
| Q2 2021 | $2,094,000 | – | 81,739 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |